Ipamorelin

Growth Hormone Secretagogues

aka NNC 26-0161 · IPAM

Compare

Formula

MW (Da)

Half-life

~2 hours

Saves

Overview

Ipamorelin is a synthetic pentapeptide developed as a selective growth-hormone secretagogue. Its main pharmacologic attraction relative to hexarelin is selectivity: it stimulates GH cleanly and, in profiling work, does not materially raise ACTH or cortisol.

Mechanism

Preclinical pharmacology showed ipamorelin acts through a GHRP-like receptor, now understood as GHSR (the ghrelin receptor), with potency and efficacy similar to older GHRPs for GH release but with a much lower effect on the pituitary-adrenal axis. In profiling studies, ipamorelin did not meaningfully increase ACTH or cortisol even at doses far above the GH-releasing ED50, which is the core mechanistic distinction from hexarelin.

0

Vendors

—

no vendors yet

Lowest price

—

Reported benefits

Selective human GH release

In a healthy-volunteer PK/PD study, ipamorelin produced a single GH secretory episode at every tested infusion rate, with a human terminal half-life of about 2 hours.

[gobburu-pkpd]

clinical

Mechanistic selectivity over ACTH/cortisol

Preclinical pharmacology confirmed that ipamorelin does not meaningfully increase ACTH or cortisol even at doses far above the GH-releasing ED50.

[raun-ipamorelin]

preclinical

GI motility indication did not show clear clinical efficacy

In a postoperative ileus phase II study, 0.03 mg/kg IV twice daily was well tolerated but did not produce significant differences from placebo in key efficacy analyses, despite a numerical trend toward faster return of tolerated meals.

[beck-poi-trial]

clinical

Reported side effects

Adverse events in line with surgical setting
clinical
Overall treatment-emergent adverse events occurred in 87.5% of the ipamorelin group and 94.8% of placebo in the bowel-resection trial, suggesting the AE burden was driven by the postoperative setting rather than obvious drug toxicity.
Long-term outpatient incidence-level safety poorly defined
anecdotal
No standardized chronic outpatient regimen is described in primary human studies; long-term outpatient incidence-level safety remains poorly characterized.

Dosing notes

Human PK/PD work used 15-minute IV infusions across 4.21 to 140.45 nmol/kg. The postoperative ileus trial used 0.03 mg/kg IV twice daily for up to 7 days or until discharge. No validated chronic wellness-style regimen was identified in primary human studies.

Research use only. Information on this page is editorial reference, not medical or dosing advice. Always consult qualified medical guidance before use.

Storage

Research-vendor storage notes describe lyophilized material as more stable than solution, with typical recommendations of -20 C storage for dry material and -20 to -80 C for aliquoted reconstituted material; avoid repeated freeze-thaw cycles.

Vendors carrying Ipamorelin

No approved vendors are listing this peptide yet. Check back later or browse the full vendor directory.

Discussion

Ask, answer, and vote on questions about Ipamorelin.

No questions yet. Be the first to ask.

References

[raun-ipamorelin]
Ipamorelin, the first selective growth hormone secretagogue
Raun K et al. · 1998 · European Journal of Endocrinology
Source
[gobburu-pkpd]
Pharmacokinetic-pharmacodynamic modeling of ipamorelin in healthy volunteers
Gobburu JVS et al. · Pharmaceutical Research
Source
[beck-poi-trial]
Ipamorelin for postoperative ileus phase II trial
Beck DE et al. · PubMed
Source